Pro 2014-029 (Jianfeng Group's First Extraordinary Shareholders' Meeting in 2014)-1
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2014-029
Bond Abbreviation: 13 Jianfeng 01 Bond Code: 122227
Zhejiang Jianfeng Group Co., Ltd.
Announcement of Resolutions of the First Extraordinary General Meeting in 2014
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents . |
Important Note:
1 , No Rejection or Modification of Proposals at this Meeting;
2 , no new proposal was submitted for voting at this meeting.
1. Meeting and Attendance
(I) Time and Place of Shareholders' Meeting
1, Convening Time:
Start Time of Site Meeting: 2014 11 12 (Wednesday) afternoon 14 : 30 ;
Internet voting time: 2014 11 March 12 morning 9 : 30-11 : 30 , p. m. 13 : 00-15 : 00 .
, venue of the on-site meeting:
conference room on the third floor of Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province.
(II) The shareholders and proxies present at the meeting are shown in the following table:
Number of Shareholders and Agents Attended the Meeting |
158 |
Total Number of Voting Shares (Shares) |
68314251 |
| # the proportion of 129 to the total voting shares of the company |
19.85 |
of which: 1. Number of shareholders and agents attending the on-site meeting |
7 |
Total number of voting shares (shares) |
57032415 |
to the total number of voting shares of the company |
16.58% |
2, number of shareholders and agents participating in online voting |
151 |
total number of voting shares (shares) |
11281836 |
as a percentage of the total voting shares of the company |
3.28% |
(III) voting method and presiding over the meeting
the notice of this meeting was published on October 28, 222 14 in 221 《 china Securities Journal, Shanghai Securities Securities News. The meeting was convened by the company's board of directors and presided over by the chairman of the board of directors, Mr. Jiang Xiaomeng. The voting method of the meeting complied with the "Company Law" and the company's "Articles of Association.
Attendance of (IV) Directors, Supervisors and Secretary of the Board of DirectorsEight current directors of the company, Chairman Jiang Xiaomeng, Directors Yu Jianhong, Huang Sujian and Independent Director Zhang Yuyou attended the meeting, while other directors were unable to attend the meeting due to business trips. The company has five current supervisors, including Li Ziqiang, Qin Xuping, Yuan Jie and Shi Fu, other supervisors were unable to attend the meeting due to business trips; Zhu Jianwei, secretary of the company's board of directors, attended the meeting; some senior executives of the company attended the meeting as nonvoting delegates.
2. Proposal Deliberation
After deliberation by shareholders and agents present at the meeting, and voting was conducted item by item by a combination of on-site registered voting and online voting, the meeting passed the following proposals:
1. Jiang Xiaomeng was elected as a director of the 9th Board of Directors;
| number of valid voting shares |
number of shares |
number of shares |
number of shares |
number of shares |
abstention number of shares |
Abstention Ratio |
Whether |
| 68314251 |
64226774 |
94.02 |
3972376 |
5.81 |
115101 |
0.17 % |
passed |
| number of valid voting shares |
number of shares |
number of shares |
number of shares |
number of shares |
abstention number of shares |
Abstention Ratio |
Whether |
| 68314251 |
64961974 |
95.09 % |
906556 |
1.33 |
2445721 |
3.58 % |
passed |
| number of valid voting shares |
number of shares |
number of shares |
number of shares |
number of shares |
abstention number of shares |
Abstention Ratio |
Whether |
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31